Safety of Single Doses of Peginesatide in Patients With Chronic Kidney Disease

NCT00109291 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2012-12-21

No results posted yet for this study

Summary

To evaluate the safety profile of single intravenous (IV) dose levels of peginesatide in participants with chronic kidney disease(CKD) not on dialysis.

Conditions

Interventions

DRUG

Placebo

DRUG

peginesatide

Sponsors & Collaborators

  • Affymax

    lead INDUSTRY

Principal Investigators

  • Affymax · Affymax, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2006-02-28
Completion
2006-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00109291 on ClinicalTrials.gov